Pharmacodynamics and Receptor Theory

Receptors & Dose-Response - Binding & Bending

• Receptors: Cellular macromolecules drugs bind to initiate effects.
• Drug-Receptor Interaction:
  • Binding (Affinity): Tendency to form drug-receptor complex. Measured by $K_d$ (dissociation constant); ↓$K_d$ = ↑affinity. 📌 $K_d$ Low = Drug Loves (High Affinity).
  • Bending (Efficacy/Intrinsic Activity): Receptor conformational change after binding, leading to a response.
• Key Drug Types:
  • Agonist: Has affinity & efficacy.
  • Antagonist: Has affinity, NO efficacy; blocks agonist action.
• Dose-Response Curve (DRC) Parameters:
  • $E_{max}$: Maximal effect a drug can produce.
  • $ED_{50}$ ($EC_{50}$): Dose producing 50% of $E_{max}$; indicates potency.
  • Therapeutic Index (TI): Ratio $TD_{50}/ED_{50}$ (or $LD_{50}/ED_{50}$); reflects drug safety.

⭐ A drug with a lower $ED_{50}$ is more potent, but this does not necessarily mean it has higher efficacy (related to $E_{max}$).

Drug-Receptor Tango - Agonists & Antagonists

• Agonists: Bind receptors, elicit response. Have affinity & efficacy.
  • Full: Max response ($E_{max}$).
  • Partial: Submax response; can be antagonist with full agonist.
  • Inverse: Opposite effect of agonist (needs basal receptor activity).
• Antagonists: Bind receptors, no activation; block agonists. Have affinity, no efficacy.
  • Competitive (Reversible): 📌 Compete for agonist site. Can be overcome by ↑ agonist. Shifts Dose-Response Curve (DRC) right (↑ $ED_{50}$), $E_{max}$ unchanged.
  • Competitive (Irreversible): Binds strongly/covalently. ↓ $E_{max}$.
  • Non-competitive: Allosteric/downstream block. 📌 Not overcome by ↑ agonist. ↓ $E_{max}$.
• Key Concepts:
  • Affinity: Binding strength ($K_D$).
  • Efficacy ($E_{max}$): Max response.
  • Potency ($ED_{50}$): Dose for 50% effect.

, non-competitive antagonist (downward shift of agonist curve))

⭐ A partial agonist has lower intrinsic activity than a full agonist but can be more potent. For example, buprenorphine (partial opioid agonist) is more potent than morphine (full agonist) but has a lower $E_{max}$ anagesic effect ceiling.

Signal Cascades - Message Relays

• Extracellular signals (drug-receptor binding) converted to intracellular responses via molecular relays.

• Key Components:

  • Receptors: GPCRs, RTKs, Ion Channels, Nuclear.
  • Second Messengers (signal amplifiers): cAMP, cGMP, IP3, DAG, $Ca^{2+}$.
  • Effector Enzymes: Adenylyl cyclase (AC), Guanylyl cyclase (GC), Phospholipase C (PLC).
  • Protein Kinases (phosphorylate targets): PKA, PKG, PKC, Tyrosine kinases.
  • Protein Phosphatases (dephosphorylate targets): Reverse kinase action.

• Other Major Pathways:

  • Receptor Tyrosine Kinases (RTKs): e.g., Insulin. Ligand binding → dimerization → autophosphorylation → SH2 domain protein docking → Ras-MAPK pathway.
  • Guanylyl Cyclase (GC) Pathway: e.g., ANP, NO. ↑ cGMP → PKG activation.
  • Ligand-gated Ion Channels: Rapid signaling, e.g., nAChR, GABA-A receptor.

⭐ Most G-protein coupled receptors (GPCRs) transduce signals via adenylyl cyclase/cAMP or phospholipase C/IP3-DAG pathways.

​

Receptor Dynamics & Safety - Ups, Downs & Windows

• Receptor Regulation:
  • Tachyphylaxis: Acute, rapid ↓ drug response (e.g., ephedrine, nitrates).
  • Desensitization: ↓ receptor responsiveness.
  • Downregulation: ↓ receptor number (chronic agonist).
  • Upregulation: ↑ receptor number (chronic antagonist).
• Drug Safety & Efficacy:
  • Therapeutic Index (TI): $TI = \frac{TD_{50}}{ED_{50}}$. Higher TI = safer.
  • Therapeutic Window: Range between Min. Effective Conc. (MEC) & Min. Toxic Conc. (MTC).

  ⭐ Drugs with a narrow therapeutic index (e.g., Digoxin, Warfarin, Phenytoin) require therapeutic drug monitoring (TDM).

  • 📌 NTI Drugs (Mnemonic: Warning These Drugs Are Lethal Potentially): Warfarin, Theophylline, Digoxin, Aminoglycosides, Lithium, Phenytoin.

High‑Yield Points - ⚡ Biggest Takeaways

• Receptors are key drug targets, mostly proteins, mediating pharmacological effects.
• Affinity is binding strength; Intrinsic Activity is response elicitation capacity.
• Agonists possess both; Antagonists have affinity but zero intrinsic activity.
• Potency (EC₅₀) reflects dose for 50% effect; Efficacy (Eₘₐₓ) is maximal response.
• Spare receptors allow maximal response without full receptor occupancy.
• Therapeutic Index (TI = TD₅₀/ED₅₀) indicates drug safety margin.
• Receptor desensitization (downregulation) occurs with chronic agonist exposure.